Please Wait.....
Report
Gastrointestinal Stromal Tumor (GIST) - Market Insight, Epidemiology And Market Forecast - 2032
Market Report I 2022-08-01 I 240 Pages I DelveInsight
DelveInsight's 'Gastrointestinal Stromal Tumor (GIST)-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the GIST, historical and forecasted epidemiology as well as the GIST market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The GIST market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM GIST market size from 2019 to 2032. The Report also covers current GIST treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Gastrointestinal Stromal Tumor (GIST) Disease Understanding and Treatment Algorithm
As per GIST Support International, gastrointestinal stromal tumor (GIST) is rare cancer affecting the digestive tract or nearby structures within the abdomen. It is a sarcoma that arises either from cells called interstitial cells of Cajal (ICCs) or from less differentiated stem cells or precursor cells that can develop into ICCs.
GIST progression is driven by mutations in KIT or PDGFRA or by other rare gene alterations, all of which are mutually exclusive. It is known that the majority of tumors of GIST will have mutations in the KIT gene, and a minority, in the PDGFR gene.
Wild-type GIST do not have mutations of the KIT or PDGFR genes. Some of the cases of wild-type GIST have been linked to genes involved in the succinate dehydrogenase (SDH) enzyme complex (i.e., SDHA, SDHB, SDHC, or SDHD genes). Additional genes have been linked to wild-type GIST, includes BRAF, KRAS, and NRAS mutations.
Gastrointestinal Stromal Tumor (GIST) Diagnosis
A GIST diagnosis is typically made or ruled out based on a patient's medical history, a comprehensive physical examination, and the results of a series of tests. The testing methods used to confirm or rule out a GIST can vary based on a patient's symptoms and other individual factors.
After physical examination, CT scan (CAT scan), MRI, Endoscopic ultrasound and biopsy, Immunohistochemistry, Mitotic rate, PET scan can be performed to confirm the disease and its severity.
Continued in the report..
Gastrointestinal Stromal Tumor (GIST) Treatment
Gastrointestinal stromal tumor (GIST) is the most frequent malignant mesenchymal tumors in the gastrointestinal tract. The initial work-up with endoscopy and endoscopic ultrasonography plays important roles in the differential diagnosis of GIST. Surgery is the only modality for the permanent cure of localized GISTs. In terms of safety and prognostic outcomes, laparoscopy is similar to laparotomy for GIST treatment, including tumors larger than 5 cm. GIST progression is driven by mutations in KIT or PDGFRA or by other rare gene alterations, all of which are mutually exclusive.
Tyrosine kinase inhibitors (TKIs) are the standard therapy for metastatic/recurrent GIST. Molecular alterations are the most reliable biomarkers for TKIs and for other drugs, such as NTRK inhibitors. The pathological and genetic diagnosis prior to treatment has been challenging; however, a newly developed endoscopic device may be useful for diagnosis. In the era of precision medicine, cancer genome profiling by targeted gene panel analysis may enable potential targeted therapy even for GIST without KIT or PDGFRA mutations.
Gastrointestinal Stromal Tumor (GIST) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total incident cases of GIST, Gender-specific Incident Cases of GIST, Age-specific Incident Cases of GIST, Incident Cases of GIST by Mutation, and Stage-specific Incident Cases of GIST in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Key Findings
- In the assessment done by DelveInsight, the estimated total incident cases of GIST in the 7MM were 14,251 in 2021.
- The highest incident cases of GIST were accounted by the US in 2021 (6,035 cases), which are expected to show a steep rise soon due to the improvement in diagnostic testing and advancements in genetic testing and accounts for 42% of the total cases in the 7MM.
- In 2021, the age-specific incident cases of GIST accounted highest in the age group 66-80 years with 5,384 cases in the 7MM, followed by age group 51-65 years with 4,581 cases. While the least number of cases were seen in the age group 0-17 years.
- Among the European countries, Germany had the highest incident population of GIST with 1,736 cases, followed by Italy, which had incident population of 1,095 in 2021. On the other hand, Spain had the lowest incident population (824 cases).
- Japan had 2,458 incident cases for GIST in 2021, accounting for approximately 17% of total incident cases in the 7MM.
Gastrointestinal Stromal Tumor (GIST) Epidemiology
The epidemiology segment also provides the Gastrointestinal Stromal Tumor (GIST) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Gastrointestinal Stromal Tumor (GIST) Drug Chapters
The drug chapter segment of the Gastrointestinal Stromal Tumor (GIST) report encloses the detailed analysis of Gastrointestinal Stromal Tumor (GIST) marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Gastrointestinal Stromal Tumor (GIST) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.
Gastrointestinal Stromal Tumor (GIST) Marketed Drugs
Gleevec/Glivec (Imatinib Mesylate): Novartis
Gleevec is a kinase inhibitor indicated for treating patients with Kit (CD117) positive unresectable and/or metastatic malignant GIST. It is also used as adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.
In addition, it is used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia, myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangement, and adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)
Products detail in the report?
Qinlock (Ripretinib): Deciphera Pharmaceuticals
Qinlock (Ripretinib) is an orally administered switch-control kinase inhibitor engineered using a proprietary drug discovery platform and developed for the treatment of GIST. While approved kinase inhibitors control certain initiating and drug resistance-causing mutations in KIT and PDGFRA, the kinases that drive disease progression in most GIST patients, these approved drugs fail to inhibit all known mutations. Qinlock improves the treatment of GIST patients by inhibiting the full spectrum of the known mutations in KIT and PDGFRA. It is a KIT and PDGFRA switch-control kinase inhibitor that blocks initiating and resistance KIT mutations in exons 9, 11, 13, 14, 17, and 18 known to be present in GIST patients.
Products detail in the report
List to be continued in the report
Gastrointestinal Stromal Tumor (GIST) Emerging Drugs
Crenolanib: Arog Pharmaceutical
Crenolanib is a small molecule investigational drug candidate that is being evaluated for safety and efficacy in Phase III clinical trials in acute myeloid leukemia (AML) and gastrointestinal stromal tumor (GIST). Crenolanib is a potent small-molecule inhibitor of wild-type and mutant forms of FLT3 (FMS-like Tyrosine Kinase 3) and PDGFR?/? (Platelet-derived Growth Factor Receptor).
The US FDA had granted Fast Track designation for Crenolanib to treat patients with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFR?) D842V mutation.
Products detail in the report
TAS-116: Taiho Pharmaceutical
TAS-116 is an oral compound discovered by Taiho Pharmaceutical, inhibits HSP90, thereby showing an anticancer effect by destabilizing and reducing proteins such as KIT, PDGFRA, HER2, and EGFR involved in the growth and survival of cancer. TAS-116 is a nonansamycin, nonpurine, nonresorcinol, highly selective inhibitor of HSP90?/? with antitumor activity in an imatinib-resistant human GIST xenograft mouse model.
Currently, the molecule is in Phase III clinical development for GIST in Japan and for solid tumors in Phase I clinical development in the US and Europe.
Products detail in the report
List to be continued in the report
Gastrointestinal Stromal Tumor (GIST) Market Outlook
Knowledge about the underlying genetic alterations revealed possible targeted treatment with TKIs such as imatinib and sunitinib. Continuous research efforts helped to further elucidate molecular insights of this disease and allowed the development of new treatment options based on the underlying molecular signature. Currently, there are seven therapies approved for GIST that includes five TKIs, and two NTRK inhibitors such as Gleevec (Imatinib Mesylate), Stivarga (Regorafenib), Sutent (sunitinib malate), Ayvakit (avapritinib), Qinlock (Ripretinib), Rozlytrek (Entrectinib), and Vitrakvi (Larotrectinib), approved in different lines. Along with these, there are certain therapies being used as off-label therapies in patients resistant to approved therapies.
Targeted therapy with imatinib, an oral, small molecule, selective tyrosine-kinase inhibitor of KIT, PDGFRA, and ABL that was approved for first-line treatment for advanced GIST in 2002, for adjuvant treatment in high-risk patients in 2008, and for use in adult patients following surgical removal of CD117-positive GIST in 2012 by USFDA (the United States Food and Drug Administration), in 2001 by EMA (European Medicines Agency), and 2003 by PMDA (Pharmaceuticals and Medical Devices Agency), revolutionized treatment for GIST. Though the management of GIST was transformed after the arrival of imatinib which became the standard first-line treatment for metastatic GIST. On the other hand, despite a clinical benefit rate of 80%, half of those having a clinical benefit eventually progress after 2 years of therapy due to acquired imatinib resistance.
Continued in the report..
Key Findings
- The therapeutic market of GIST in the 7MM was USD 450 million in 2021.
- The United States accounts for the highest market size of GIST approximately 67% of the total market size in 7MM in 2021, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
- Among the EU5 countries, Germany had the highest market size with USD 33 million in 2021, while Spain had the lowest market size of GIST with USD 17 million in 2021.
- The market size for GIST in Japan was estimated to be USD 36 Million in 2021, which accounts for 8% of the total 7MM market.
- With the expected launch of upcoming therapies, such as Crenolanib, Bezuclastinib (CGT9486/PLX9486), and others the total market of GIST is expected to show a decent change in upcoming years.
The United States Market Outlook
This section provides the total Gastrointestinal Stromal Tumor (GIST) market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total Gastrointestinal Stromal Tumor (GIST) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Gastrointestinal Stromal Tumor (GIST) market size and market size by therapies in Japan are provided.
Gastrointestinal Stromal Tumor (GIST) Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the GIST market or expected to get launched in the market during the study period 2019-2032. The analysis covers GIST market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Gastrointestinal Stromal Tumor (GIST) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Gastrointestinal Stromal Tumor (GIST) emerging therapies.
Reimbursement Scenario in Gastrointestinal Stromal Tumor (GIST)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Gastrointestinal Stromal Tumor (GIST) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of GIST, explaining its signs and symptoms, causes, classification, and currently available therapies.
- Comprehensive insight has been provided into the GIST epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for GIST is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the GIST market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM GIST market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the GIST market.
- The companies and academics are working to assess challenges and seek opportunities that could influence GIST R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition and underlying cause.
- Major players are involved in developing therapies for GIST. The launch of emerging therapies will significantly impact the GIST market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Gastrointestinal Stromal Tumor (GIST) Report Insights
- Patient Population
- Therapeutic Approaches
- GIST Pipeline Analysis
- GIST Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Gastrointestinal Stromal Tumor (GIST) Report Key Strengths
- 11-Years Forecast
- 7MM Coverage
- GIST Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Gastrointestinal Stromal Tumor (GIST) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Key Questions
Market Insights:
- What was the GIST's market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the GIST's total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest GIST market size during the forecast period (2022-2032)?
- At what CAGR, the GIST market is expected to grow at the 7MM level during the forecast period (2022-2032)?
- What would be the GIST market outlook across the 7MM during the forecast period (2022-2032)?
- What would be the GIST market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden, and unmet needs of GIST?
- What is the historical GIST patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient population of GIST at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to GIST?
- Out of the above-mentioned countries, which country would have the highest incident population of GIST during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of GIST along with the approved therapy?
- What are the current treatment guidelines for the treatment of GIST in the US and Europe?
- What are the GIST marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of GIST?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of GIST?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the GIST therapies?
- What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for GIST and their status?
- What are the key designations that have been granted for the emerging therapies for GIST?
- What are the 7MM historical and forecasted market of GIST?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the GIST.
- To understand the future market competition in the GIST market and an Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for GIST in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the GIST market.
- To understand the future market competition in the GIST market.
1. Key Insights
2. Report Introduction
3. Gastrointestinal Stromal Tumor Market Overview at a Glance
3.1. Market Share (%) Distribution of Gastrointestinal Stromal Tumor in 2019
3.2. Market Share (%) Distribution of Gastrointestinal Stromal Tumor in 2032
4. Gastrointestinal Stromal Tumor Market: Future Perspective
5. Executive Summary of Gastrointestinal Stromal Tumors
6. Key Events
7. Gastrointestinal Stromal Tumor: Disease Background and Overview
7.1. Introduction of Gastrointestinal Stromal Tumor
7.2. Etiology of Gastrointestinal Stromal Tumor
7.3. Signs and Symptoms of Gastrointestinal Stromal Tumor
7.4. Risk Factors of Gastrointestinal Stromal Tumor
7.5. Classification of Gastrointestinal Stromal Tumor Based on Mutations
7.6. Pathophysiology of Gastrointestinal Stromal Tumor
7.7. Pathogenesis of Gastrointestinal Stromal Tumor
7.8. Genetic Background of Gastrointestinal Stromal Tumor
7.9. Biomarkers Associated With Gastrointestinal Stromal Tumor
7.10. Diagnosis of Gastrointestinal Stromal Tumor
7.10.1. Diagnostic Guidelines of Gastrointestinal Stromal Tumor
7.10.1.1. NCCN guidelines for GIST
7.10.1.2. ESMO-EURACAN clinical practice guidelines for diagnosis, treatment, and follow-up of GIST
7.10.1.3. British Sarcoma Group guidelines for the management of GIST
7.10.1.4. Japan Cancer Treatment Society's GIST clinical practice guidelines
7.11. Treatment and Management of Gastrointestinal Stromal Tumor
7.11.1. Treatment Algorithm
7.11.2. Treatment Guidelines
7.11.2.1. NCCN Guidelines for Gastrointestinal Stromal Tumors
7.11.2.2. ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
7.11.2.3. British Sarcoma Group Guidelines for the Management of GIST
7.11.2.4. Japan Cancer Treatment Society's GIST clinical practice guidelines
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Epidemiology Methodology
8.3. Assumptions and Rationale: Seven Major Market
8.3.1. The United States
8.3.2. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
8.3.3. Japan
8.4. Total Incident Cases of Gastrointestinal Stromal Tumor in the 7MM
8.5. The United States
8.5.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.5.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.5.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.5.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.5.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
8.6.1. Germany
8.6.1.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.6.1.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.1.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.1.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.1.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.2. France
8.6.2.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.6.2.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.2.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.2.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.2.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.3. Italy
8.6.3.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.6.3.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.3.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.3.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.3.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.4. Spain
8.6.4.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.6.4.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.4.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.4.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.4.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.5. The United Kingdom
8.6.5.1. Total Incident Cases of Gastrointestinal Stromal Tumor
8.6.5.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.5.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.5.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor
8.6.5.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor
8.7. Japan
8.7.1. Total Incident Cases of Gastrointestinal Stromal Tumor in Japan
8.7.2. Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan
8.7.3. Age-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan
8.7.4. Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan
8.7.5. Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan
9. Patient Journey
10. Marketed Drugs
10.1. Key Competitors
10.2. Gleevec/Glivec (Imatinib Mesylate): Novartis
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental Activities
10.2.4. Clinical Development
10.2.5. Clinical Trials Information
10.2.6. Safety and efficacy
10.2.7. Product Profile
10.3. Stivarga (Regorafenib): Bayer
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Other Developmental Activities
10.3.4. Clinical Development
10.3.5. Clinical Trials Information
10.3.6. Safety and efficacy
10.3.7. Product Profile
10.4. Sutent (Sunitinib malate): Pfizer
10.4.1. Product Description
10.4.2. Regulatory Milestones
10.4.3. Other Developmental Activities
10.4.4. Clinical Development
10.4.5. Clinical Trials Information
10.4.6. Safety and efficacy
10.4.7. Product Profile
10.5. Qinlock (Ripretinib): Deciphera Pharmaceuticals
10.5.1. Product Description
10.5.2. Regulatory Milestones
10.5.3. Other Development Activities
10.5.4. Clinical Development
10.5.5. Clinical Trials Information
10.5.6. Safety and Efficacy
10.5.7. Product Profile
10.6. Ayvakit (Avapritinib): Blueprint Medicines Corporation
10.6.1. Product Description
10.6.2. Regulatory Milestones
10.6.3. Other Development Activities
10.6.4. Clinical Development
10.6.5. Clinical Trials Information
10.6.6. Safety and Efficacy
10.6.7. Product Profile
10.7. Vitrakvi (Larotrectinib; BAY2757556): Bayer/Loxo Oncology
10.7.1. Product Description
10.7.2. Regulatory Milestones
10.7.3. Other Development Activities
10.7.4. Clinical Development
10.7.5. Clinical Trials Information
10.7.6. Safety and efficacy
10.7.7. Product Profile
10.8. Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)
10.8.1. Product Description
10.8.2. Regulatory Milestones
10.8.3. Other Development Activities
10.8.4. Clinical Development
10.8.5. Clinical trial information
10.8.6. Safety and Efficacy of Rozlytrek
10.8.7. Product Profile
11. Emerging Drugs
11.1. Key Competitors
11.2. Crenolanib: Arog Pharmaceuticals
11.2.1. Product Description
11.2.2. Other Development Activities
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3. TAS-116: Taiho Pharmaceutical
11.3.1. Product Description
11.3.2. Other Development Activities
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.4. Repotrectinib: Turning Point Therapeutics, Inc.
11.4.1. Product Description
11.4.2. Development Activities
11.4.3. Clinical Development
11.4.4. Clinical Trials Information
11.4.5. Safety and Efficacy
11.4.6. Product Profile
11.5. Bezuclastinib (CGT9486/PLX9486): Cogent Biosciences, Inc. / Plexxikon Inc.
11.5.1. Product Description
11.5.2. Other Development Activities
11.5.3. Clinical Development
11.5.4. Clinical Trials Information
11.5.5. Safety and Efficacy
11.5.6. Product Profile
11.5.7. Analysts' Views
11.6. THE-630: Theseus Pharmaceuticals
11.6.1. Product Description
11.6.2. Other Development Activities
11.6.3. Clinical Development
11.6.4. Clinical Trials Information
11.6.5. Product Profile
11.6.6. Analysts' Views
11.7. Cabozantinib: Exelixis, Inc./Ipsen/Takeda
11.7.1. Product Description
11.7.2. Other Development Activities
11.7.3. Clinical Development
11.7.4. Clinical Trials Information
11.7.5. Safety and Efficacy
11.7.6. Product Profile
11.8. Opdivo (nivolumab) With/Without Yervoy (Ipilimumab): Bristol-Myers Squibb
11.8.1 Product Description
11.8.2 Other Development Activities
11.8.3 Clinical Development
11.8.4 Clinical Trials Information
11.8.5 Product Profile
12. Gastrointestinal Stromal Tumor: Seven Major Market Analysis
12.1. Key Findings
12.2. Market Methodology
12.3. Market Size of Gastrointestinal Stromal Tumor in the 7MM
12.4. Market Size of Gastrointestinal Stromal Tumor by Therapies in the 7MM
12.4.1. Market Size of Gastrointestinal Stromal Tumor by First-line Therapies in the 7MM
12.4.2. Market Size of Gastrointestinal Stromal Tumor by Second-line Therapies in the 7MM
12.4.3. Market Size of Gastrointestinal Stromal Tumor by Third-line Therapies in the 7MM
12.4.4. Market Size of Gastrointestinal Stromal Tumor by Fourth-line+ Therapies in the 7MM
12.4.5. Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the 7MM
12.5. Potential of Current and Emerging Therapies
12.6. Key Market Forecast Assumptions
12.7. Market Outlook
12.8. Market Size of Gastrointestinal Stromal Tumor in the United States
12.8.1. Total Market Size of Gastrointestinal Stromal Tumor
12.8.2. Market Size of Gastrointestinal Stromal Tumor by Therapies
12.8.2.1. Market Size of Gastrointestinal Stromal Tumor by First-line Therapies in the US
12.8.2.2. Market Size of Gastrointestinal Stromal Tumor by Second-line Therapies in the US
12.8.2.3. Market Size of Gastrointestinal Stromal Tumor by Third-line Therapies in the US
12.8.2.4. Market Size of Gastrointestinal Stromal Tumor by Fourth-line Therapies in the US
12.8.2.5. Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the US
12.9. Market Size of Gastrointestinal Stromal Tumor in the EU-5
12.9.1. Total Market Size of Gastrointestinal Stromal Tumor
12.9.2. Market Size of Gastrointestinal Stromal Tumor by Therapies
12.9.2.1. Market Size of Gastrointestinal Stromal Tumor by First-line Therapies in the EU-5
12.9.2.2. Market Size of Gastrointestinal Stromal Tumor by Second-line Therapies in the EU-5
12.9.2.3. Market Size of Gastrointestinal Stromal Tumor by Third-line Therapies in the EU-5
12.9.2.4. Market Size of Gastrointestinal Stromal Tumor by Fourth-line Therapies in the EU-5
12.9.2.5. Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the EU-5
12.10. Market Size of Gastrointestinal Stromal Tumor in Germany
12.10.1. Total Market Size of Gastrointestinal Stromal Tumor
12.10.2. Market Size of Gastrointestinal Stromal Tumor by Therapies
12.10.2.1. Market Size of Gastrointestinal Stromal Tumor by First-line Therapies
12.10.2.2. Market Size of Gastrointestinal Stromal Tumor by Second-line Therapies
12.10.2.3. Market Size of Gastrointestinal Stromal Tumor by Third-line Therapies
12.10.2.4. Market Size of Gastrointestinal Stromal Tumor by Fourth-line Therapies
12.10.2.5. Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies
12.11. Market Size of Gastrointestinal Stromal Tumor in France
12.11.1. Total Market Size of Gastrointestinal Stromal Tumor
12.11.2. Market Size of Gastrointestinal Stromal Tumor by Therapies
12.11.2.1. Market Size of Gastrointestinal Stromal Tumor by First-lineTherapies
12.11.2.2. Market Size of Gastrointestinal Stromal Tumor by Second-lineTherapies
12.11.2.3. Market Size of Gastrointestinal Stromal Tumor by Third-lineTherapies
12.11.2.4. Market Size of Gastrointestinal Stromal Tumor by Fourth-line Therapies
12.11.2.5. Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies
12.12. Market Size of Gastrointestinal Stromal Tumor in Italy
12.12.1. Total Market Size of Gastrointestinal Stromal Tumor
12.12.2. Market Size of Gastrointestinal Stromal Tumor by Therapies
12.12.2.1. Market Size of Gastrointestinal Stromal Tumor by First-line Therapies
12.12.2.2. Market Size of Gastrointestinal Stromal Tumor by Second-line Therapies
12.12.2.3. Market Size of Gastrointestinal Stromal Tumor by Third-line Therapies
12.12.2.4. Market Size of Gastrointestinal Stromal Tumor by Fourth-line Therapies
12.12.2.5. Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies
12.13. Market Size of Gastrointestinal Stromal Tumor in Spain
12.13.1. Total Market Size of Gastrointestinal Stromal Tumor
12.13.2. Market Size of Gastrointestinal Stromal Tumor by Therapies
12.13.2.1. Market Size of Gastrointestinal Stromal Tumor by First-lineTherapies
12.13.2.2. Market Size of Gastrointestinal Stromal Tumor by Second-lineTherapies
12.13.2.3. Market Size of Gastrointestinal Stromal Tumor by Third-lineTherapies
12.13.2.4. Market Size of Gastrointestinal Stromal Tumor by Fourth-line Therapies
12.13.2.5. Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies
12.14. Market Size of Gastrointestinal Stromal Tumor in the UK
12.14.1. Total Market Size of Gastrointestinal Stromal Tumor
12.14.2. Market Size of Gastrointestinal Stromal Tumor by Therapies
12.14.2.1. Market Size of Gastrointestinal Stromal Tumor by First-lineTherapies
12.14.2.2. Market Size of Gastrointestinal Stromal Tumor by Second-line Therapies
12.14.2.3. Market Size of Gastrointestinal Stromal Tumor by Third-line Therapies
12.14.2.4. Market Size of Gastrointestinal Stromal Tumor by Fourth-line Therapies
12.14.2.5. Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies
12.15. Market Size of Gastrointestinal Stromal Tumor in Japan
12.15.1. Total Market Size of Gastrointestinal Stromal Tumor
12.15.2. Market Size of Gastrointestinal Stromal Tumor by Therapies
12.15.2.1. Market Size of Gastrointestinal Stromal Tumor by First-lineTherapies in Japan
12.15.2.2. Market Size of Gastrointestinal Stromal Tumor by Second-lineTherapies in Japan
12.15.2.3. Market Size of Gastrointestinal Stromal Tumor by Third-lineTherapies in Japan
12.15.2.4. Market Size of Gastrointestinal Stromal Tumor by Fourth-line+ Therapies in Japan
12.15.2.5. Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in Japan
13. Key Opinion Leaders' Views
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. Reimbursement and Market Access
19. Appendix
19.1. Bibliography
19.2. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Table 1: Summary of Gastrointestinal Stromal Tumor Market and Epidemiology (2019-2032)
Table 2: Key Events
Table 3: Diagnosis of GIST
Table 4: Additional Options After Failure on Approved Therapies
Table 5: Total Incident Cases of Gastrointestinal Stromal Tumor in the 7MM (2019-2032)
Table 6: Total Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Table 7: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Table 8: Age-specific Incident of Gastrointestinal Stromal Tumor in the US (2019-2032)
Table 9: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Table 10: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Table 11: Total Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Table 12: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Table 13: Age-specific Incident of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Table 14: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Table 15: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Table 16: Total Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Table 17: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Table 18: Age-specific Incident of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Table 19: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Table 20: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Table 21: Total Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Table 22: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Table 23: Age-specific Incident of Gastrointestinal Stromal Tumor in France (2019-2032)
Table 24: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Table 25: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Table 26: Total Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Table 27: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Table 28: Age-specific Incident of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Table 29: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Table 30: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Table 31: Total Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Table 32: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Table 33: Age-specific Incident of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Table 34: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Table 35: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Table 36: Total Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Table 37: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Table 38: Age-specific Incident of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Table 39: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Table 40: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Table 41: Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Table 42: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Table 43: Age-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Table 44: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Table 45: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Table 46: Comparison of Marketed Drugs Under Development
Table 47: Gleevec (Imatinib Mesylate), Clinical Trial Description, 2022
Table 48: Stivarga, Clinical Trial Description, 2022
Table 49: Sutent; Clinical Trial Description, 2022
Table 50: Qinlock (Ripretinib), Clinical Trial Description, 2022
Table 51: Ayvakit (avapritinib), Clinical Trial Description, 2022
Table 52: Vitrakvi, Clinical Trial Description, 2022
Table 53: Comparison of Emerging Drugs Under Development
Table 54: Crenolanib, Clinical Trial Description, 2022
Table 55: TAS-116, Clinical Trial Description, 2022
Table 56: CGT9486, Clinical Trial Description, 2022
Table 57: THE-630, Clinical Trial Description, 2022
Table 58: Cabozantinib, Clinical Trial Description, 2022
Table 59: PBI-200, Clinical Trial Description, 2022
Table 60: Expected Patent Expiration Year
Table 61: Opdivo (Nivolumab) With/Without YERVOY (Ipilimumab), Clinical Trial Description, 2022
Table 62: Repotrectinib, Clinical Trial Description, 2022
Table 63: Market Size of Gastrointestinal Stromal Tumor in the 7MM, in USD Million (2019-2032)
Table 64: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in the 7MM, in USD Million (2019-2032)
Table 65: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in the 7MM, in USD Million (2019-2032)
Table 66: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in the 7MM, in USD Million (2019-2032)
Table 67: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in the 7MM, in USD Million (2019-2032)
Table 68: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the 7MM, in USD Million (2019-2032)
Table 69: Key Market Forecast Assumptions for Crenolanib
Table 70: Key Market Forecast Assumptions for Pimitespib (TAS-116)
Table 71: Key Market Forecast Assumptions for Bezuclastinib
Table 72: Key Market Forecast Assumptions for Opdivo (nivolumab) With/Without Yervoy (Ipilimumab)
Table 73: Key Market Forecast Assumptions for Cabozantinib
Table 74: United States Market Size of Gastrointestinal Stromal Tumor in USD Million (2019-2032)
Table 75: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in the United States, in USD Million (2019-2032)
Table 76: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in the United States, in USD Million (2019-2032)
Table 77: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in the United States, in USD Million (2019-2032)
Table 78: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line Therapies in the United States, in USD Million (2019-2032)
Table 79: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the United States, in USD Million (2019-2032)
Table 80: EU-5 Market Size of Gastrointestinal Stromal Tumor in USD Million (2019-2032)
Table 81: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in the EU-5, in USD Million (2019-2032)
Table 82: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in the EU-5, in USD Million (2019-2032)
Table 83: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in the EU-5, in USD Million (2019-2032)
Table 84: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in the EU-5, in USD Million (2019-2032)
Table 85: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the EU-5, in USD Million (2019-2032)
Table 86: Market Size of Gastrointestinal Stromal Tumor in Germany, in USD Million (2019-2032)
Table 87: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in Germany, in USD Million (2019-2032)
Table 88: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in Germany, in USD Million (2019-2032)
Table 89: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in Germany, in USD Million (2019-2032)
Table 90: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in Germany, in USD Million (2019-2032)
Table 91: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in Germany, in USD Million (2019-2032)
Table 92: Market Size of Gastrointestinal Stromal Tumor in France, in USD Million (2019-2032)
Table 93: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in France, in USD Million (2019-2032)
Table 94: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in France, in USD Million (2019-2032)
Table 95: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in France, in USD Million (2019-2032)
Table 96: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in France, in USD Million (2019-2032)
Table 97: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in France, in USD Million (2019-2032)
Table 98: Market Size of Gastrointestinal Stromal Tumor in Italy, in USD Million (2019-2032)
Table 99: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in Italy, in USD Million (2019-2032)
Table 100: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in Italy, in USD Million (2019-2032)
Table 101: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in Italy, in USD Million (2019-2032)
Table 102: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in Italy, in USD Million (2019-2032)
Table 103: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in Italy, in USD Million (2019-2032)
Table 104: Market Size of Gastrointestinal Stromal Tumor in Spain, in USD Million (2019-2032)
Table 105: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in Spain, in USD Million (2019-2032)
Table 106: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in Spain, in USD Million (2019-2032)
Table 107: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in Spain, in USD Million (2019-2032)
Table 108: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in Spain, in USD Million (2019-2032)
Table 109: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in Spain, in USD Million (2019-2032)
Table 110: Market Size of Gastrointestinal Stromal Tumor in the UK, in USD Million (2019-2032)
Table 111: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in the UK, in USD Million (2019-2032)
Table 112: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in the UK, in USD Million (2019-2032)
Table 113: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in the UK, in USD Million (2019-2032)
Table 114: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in the UK, in USD Million (2019-2032)
Table 115: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the UK, in USD Million (2019-2032)
Table 116: Market Size of Gastrointestinal Stromal Tumor in Japan, in USD Million (2019-2032)
Table 117: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in Japan, in USD Million (2019-2032)
Table 118: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in Japan, in USD Million (2019-2032)
Table 119: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in Japan, in USD Million (2019-2032)
Table 120: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in Japan, in USD Million (2019-2032)
Table 121: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in Japan, in USD Million (2019-2032)
Figure 1: Summary of Gastrointestinal Stromal Tumor Market and Epidemiology (2019-2032)
Figure 2: Key Events
Figure 3: Diagnosis of GIST
Figure 4: Additional Options After Failure on Approved Therapies
Figure 5: Total Incident Cases of Gastrointestinal Stromal Tumor in the 7MM (2019-2032)
Figure 6: Total Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Figure 7: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Figure 8: Age-specific Incident of Gastrointestinal Stromal Tumor in the US (2019-2032)
Figure 9: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Figure 10: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2019-2032)
Figure 11: Total Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Figure 12: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Figure 13: Age-specific Incident of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Figure 14: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Figure 15: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2019-2032)
Figure 16: Total Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Figure 17: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Figure 18: Age-specific Incident of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Figure 19: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Figure 20: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2019-2032)
Figure 21: Total Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Figure 22: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Figure 23: Age-specific Incident of Gastrointestinal Stromal Tumor in France (2019-2032)
Figure 24: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Figure 25: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2019-2032)
Figure 26: Total Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Figure 27: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Figure 28: Age-specific Incident of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Figure 29: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Figure 30: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2019-2032)
Figure 31: Total Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Figure 32: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Figure 33: Age-specific Incident of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Figure 34: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Figure 35: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2019-2032)
Figure 36: Total Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Figure 37: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Figure 38: Age-specific Incident of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Figure 39: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Figure 40: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2019-2032)
Figure 41: Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Figure 42: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Figure 43: Age-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Figure 44: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Figure 45: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2019-2032)
Figure 46: Market Size of Gastrointestinal Stromal Tumor in the 7MM, in USD Million (2019-2032)
Figure 47: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in the 7MM, in USD Million (2019-2032)
Figure 48: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in the 7MM, in USD Million (2019-2032)
Figure 49: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in the 7MM, in USD Million (2019-2032)
Figure 50: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in the 7MM, in USD Million (2019-2032)
Figure 51: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the 7MM, in USD Million (2019-2032)
Figure 52: United States Market Size of Gastrointestinal Stromal Tumor in USD Million (2019-2032)
Figure 53: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in the United States, in USD Million (2019-2032)
Figure 54: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in the United States, in USD Million (2019-2032)
Figure 55: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in the United States, in USD Million (2019-2032)
Figure 56: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line Therapies in the United States, in USD Million (2019-2032)
Figure 57: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the United States, in USD Million (2019-2032)
Figure 58: EU-5 Market Size of Gastrointestinal Stromal Tumor in USD Million (2019-2032)
Figure 59: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in the EU-5, in USD Million (2019-2032)
Figure 60: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in the EU-5, in USD Million (2019-2032)
Figure 61: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in the EU-5, in USD Million (2019-2032)
Figure 62: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in the EU-5, in USD Million (2019-2032)
Figure 63: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the EU-5, in USD Million (2019-2032)
Figure 64: Market Size of Gastrointestinal Stromal Tumor in Germany, in USD Million (2019-2032)
Figure 65: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in Germany, in USD Million (2019-2032)
Figure 66: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in Germany, in USD Million (2019-2032)
Figure 67: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in Germany, in USD Million (2019-2032)
Figure 68: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in Germany, in USD Million (2019-2032)
Figure 69: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in Germany, in USD Million (2019-2032)
Figure 70: Market Size of Gastrointestinal Stromal Tumor in France, in USD Million (2019-2032)
Figure 71: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in France, in USD Million (2019-2032)
Figure 72: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in France, in USD Million (2019-2032)
Figure 73: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in France, in USD Million (2019-2032)
Figure 74: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in France, in USD Million (2019-2032)
Figure 75: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in France, in USD Million (2019-2032)
Figure 76: Market Size of Gastrointestinal Stromal Tumor in Italy, in USD Million (2019-2032)
Figure 77: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in Italy, in USD Million (2019-2032)
Figure 78: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in Italy, in USD Million (2019-2032)
Figure 79: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in Italy, in USD Million (2019-2032)
Figure 80: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in Italy, in USD Million (2019-2032)
Figure 81: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in Italy, in USD Million (2019-2032)
Figure 82: Market Size of Gastrointestinal Stromal Tumor in Spain, in USD Million (2019-2032)
Figure 83: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in Spain, in USD Million (2019-2032)
Figure 84: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in Spain, in USD Million (2019-2032)
Figure 85: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in Spain, in USD Million (2019-2032)
Figure 86: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in Spain, in USD Million (2019-2032)
Figure 87: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in Spain, in USD Million (2019-2032)
Figure 88: Market Size of Gastrointestinal Stromal Tumor in the UK, in USD Million (2019-2032)
Figure 89: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in the UK, in USD Million (2019-2032)
Figure 90: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in the UK, in USD Million (2019-2032)
Figure 91: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in the UK, in USD Million (2019-2032)
Figure 92: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in the UK, in USD Million (2019-2032)
Figure 93: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in the UK, in USD Million (2019-2032)
Figure 94: Market Size of Gastrointestinal Stromal Tumor in Japan, in USD Million (2019-2032)
Figure 95: Market Size of Gastrointestinal Stromal Tumor by First-Line Therapies in Japan, in USD Million (2019-2032)
Figure 96: Market Size of Gastrointestinal Stromal Tumor by Second-Line Therapies in Japan, in USD Million (2019-2032)
Figure 97: Market Size of Gastrointestinal Stromal Tumor by Third-Line Therapies in Japan, in USD Million (2019-2032)
Figure 98: Market Size of Gastrointestinal Stromal Tumor by Fourth-Line+ Therapies in Japan, in USD Million (2019-2032)
Figure 99: Market Size of Gastrointestinal Stromal Tumor by Emerging Therapies in Japan, in USD Million (2019-2032)
Figure 100: Market Drivers
Figure 101: Market Barriers
Figure 102: SWOT Analysis
Figure 103: Unmet Needs
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security